[Sigmoid diverticulitis in immunosuppressive drug therapy]

Area of Science:

• Gastroenterology
• Surgical Oncology
• Immunology

Context:

• Sigmoid diverticulitis is a common condition requiring surgical intervention.
• Immunosuppression, often due to organ transplantation or therapies like chemotherapy, can complicate surgical outcomes.
• Previous reports suggested higher risks for immunosuppressed patients undergoing surgery for diverticulitis.

Purpose:

• To evaluate the surgical outcomes of sigmoid diverticulitis in immunosuppressed patients.
• To compare postoperative morbidity and mortality rates between immunosuppressed and non-immunosuppressed patients undergoing surgery for sigmoid diverticulitis.

Summary:

• A retrospective study reviewed 92 patients (1986-1992) with sigmoid diverticulitis treated surgically.
• Twelve patients (13%) were immunosuppressed due to various conditions and treatments (corticosteroids, chemotherapy, transplant medications).
• Surgical approaches included Hartmann's procedure, drainage with colostomy, and sigmoid resection with or without ostomy.
• One patient died postoperatively.
• No significant difference in postoperative morbidity and mortality was observed between immunosuppressed and non-immunosuppressed groups.

Impact:

• Findings suggest that surgical management of sigmoid diverticulitis in immunosuppressed patients is as safe as in the general population.
• This challenges older assumptions and may influence clinical decision-making for this patient group.
• Highlights the importance of considering immunosuppression status in surgical risk assessment for diverticulitis.